Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Herling, Carmen D., Cymbalista, Florence, Gross-Ophoff-Mueller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael ORCID: 0000-0002-5277-4679, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Lepretre, Stephane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Doehner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Levy, Vincent (2020). Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 34 (8). S. 2038 - 2051. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Stilgenbauer, Stephan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Ibach, Stefan, Choquet, Sylvain, Dartigeas, Caroline, Cazin, Bruno, Tournilhac, Olivier, Pegourie, Brigitte, Seiler, Till M., Soekler, Martin, Zirlik, Katja, Alt, Juergen, Huber, Henriette, Bloehdorn, Johannes, Tausch, Eugen, Zenz, Thorsten, Hallek, Michael, Schetelig, Johannes, Dreger, Peter and Doehner, Hartmut (2014). Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in ultra High-risk CLL: Final Results from the CLL2O Phase II Study. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Stilgenbauer, Stephan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Mack, Silja, Buehler, Andreas, Winkler, Dirk, Zenz, Thorsten, Busch, Raymonde, Ibach, Stefan, Choquet, Sylvain, Caroline, Dartigeas, Cazin, Bruno, Tournilhac, Olivier, Seiler, Till M., Zirlik, Katja, Alt, Juergen, Soekler, Martin, Schetelig, Johannes, Dreger, Peter, Hallek, Michael and Doehner, Hartmut (2012). Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

This list was generated on Tue Apr 23 16:44:13 2024 CEST.